Introduction {#S1}
============

The prevalence of cardiovascular disease (CVD) has markedly increased as the global population ages ([@B53]; [@B6]). Important age-associated changes resulting in structural deterioration and progressive decline in cardiac function is characterized with development of left ventricular hypertrophy, systolic, and diastolic dysfunction and decreased exercise capacity ([@B18]). Although the influence of age on the heart is well-documented, the sex-specific patterns of cardiac aging in males and females are less appreciated ([@B50]). Sex-associated differences, such as a higher incidence of obstructive diseases in males compared to microvascular complications in females, contribute to the variations in cardiac outcomes persistently observed between men and women ([@B84]; [@B38]). Much of the early work into these sex-associated cardiovascular outcomes focused on the role of endogenous hormones as mediators of cardiovascular protection ([@B32]). Recent data suggest that hormonal changes alone are insufficient to fully explain these variations, and other involved biological mechanisms remain a subject of ongoing debate ([@B64]).

Mitochondrial dysfunction and increased oxidative stress have been identified as key participants in cardiac aging and associated CVD ([@B48]). Sirtuin 3 (Sirt-3) is a deacetylase enzyme primarily localized in the mitochondria involved in regulating several physiological and pathophysiological processes, including redox homeostasis, through the deacetylation and activation of various proteins ([@B41]; [@B5]). Sirt-3 directly activates the major mitochondrial antioxidant enzyme manganese superoxide dismutase (MnSOD), which scavenges reactive oxygen species (ROS) ([@B74]). Evidence has shown Sirt-3 may be down regulated during cardiac aging resulting in suppressed MnSOD activity leading to increased ROS levels ([@B39]). Subsequently, increased ROS levels can activate downstream targets, including the PI3K/Akt pathway, further exacerbating age-related cardiac hypertrophic response ([@B39]; [@B49]; [@B58]). Understanding the exact role Sirt-3 has in the aging processes remains a focus of many research groups trying to uncover key pathways and therapeutic approaches to treat age-related complications ([@B75]; [@B27]; [@B30]; [@B62]).

Polyunsaturated fatty acids (PUFAs) are metabolized through numerous metabolic pathways, including the cyclooxygenase, lipooxygenase, and cytochrome P450 (CYP) monooxygenase pathways ([@B35]). These transformations produce a plethora of lipid mediators with numerous biological functions ([@B2]; [@B44]; [@B3]). Oxidative metabolism of PUFAs can produce bioactive mediators, termed oxylipids, which are further metabolized to less bioactive diols by the epoxide hydrolase family of enzymes (EH) ([@B34]; [@B52]). Located primarily in the cytosol, the soluble form (sEH), has been implicated in the progression of multiple CVDs, including hypertension and atherosclerosis ([@B28]). The microsomal form (mEH) is also an established xenobiotic-metabolizing enzyme responsible for the biotransformation of active metabolites ([@B47]). While mEH is capable of hydrolyzing PUFA derivatives, it has been determined to have limited roles in cardiac metabolism ([@B46]; [@B22]). Cardiac sEH primarily metabolizes oxylipid mediators to less active metabolites, which often results in loss of cardioprotective properties ([@B29]). Both genetic deletion and pharmacological inhibition of sEH has been demonstrated to mediate cardioprotective, anti-inflammatory and anti-hypertensive responses, as well limit mitochondrial injury ([@B35], [@B36]; [@B21]). In humans, genetic polymorphisms increasing sEH activity are associated with poor outcomes in cardiac and renal disease, although this seems to be population-dependent ([@B24]; [@B85]; [@B67]). Numerous animal studies have demonstrated the importance of sEH in various models of CVD; however, there is limited information regarding its role in generalized cardiac aging ([@B65]; [@B51]; [@B82]; [@B3]; [@B36]). Moreover, there is limited information regarding sexual disparity in cardiac sEH with age ([@B60]; [@B69]), as such the present study investigated the impact of sEH in age- and sex-dependent cardiac differences.

MATERIALS AND METHODS {#S2}
=====================

Animals {#S2.SS1}
-------

A colony of mice with targeted deletion of the *Ephx2* gene (sEH null) with their WT littermates are maintained at the University of Alberta. Mice are conserved on a C57BL6 background. All experiments were carried out on male and female mice aged 2--4 months old (young) and 15--18 months old (middle-aged). The middle-age range, referred to hereafter as "aged," was chosen to be clinically representative of the manifestation of CVD in humans and to avoid confounding effects of frailty, which can drastically change cardiovascular phenotypes in elderly mice ([@B78]). At the appropriate age, hearts and kidneys were excised from mice following euthanasia with 100mg/kg of sodium pentobarbital. Hearts and kidneys were then rinsed in 1X PBS, flash frozen in liquid nitrogen and stored at −80°C awaiting analysis. Animal experimental protocols were approved by the University of Alberta Health Sciences Welfare Committee and were carried out in accordance with the guidelines set by the Canadian Council of Animal Care.

Cardiac Function {#S2.SS2}
----------------

Transthoracic 2D echocardiography was used for cardiac functional assessment 1 week prior to animal euthanasia. Animals were anesthetized by isoflurane (1--2%) and recordings were taken using Vevo 3100 high-resolution imaging system, 40 MHz transducer (MX550S; Visual Sonics). Visual Sonics VevoLab software was used for assessment of the cardiac images. Left ventricular interior volumes and left ventricular internal diameters (LVID) were determined from m-mode images taken at the mid-papillary level. Left ventricular ejection fraction (%EF) was calculated using the equation % EF = \[(LVEDV - LVESV)/LVEDV\] × 100. Left ventricular mass (corrected, mg) was calculated with 1.05 × \[(LVID; d + LVPW; d + IVS; d)\^3-LVID; d\^3\] × 0.8. The transmitral filling pattern was assessed by pulsed-wave Doppler imaging to determine diastolic function. The E/A ratio represents early transmitral wave (E-wave) followed by the late filling wave due to atrial "kick" (A-wave). Tissue Doppler imaging was used to describe the motion of the mitral annulus (E' and A').

Protein Expression and Immunoblot Analysis {#S2.SS3}
------------------------------------------

Western blot analysis was used to determine protein expression in subcellular mitochondrial, microsomal, and cytosolic fractions. Briefly, hearts and kidneys were homogenized in ice cold homogenization buffer (250 mM sucrose, 10 mM Tris--HCL, 1mM EDTA, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 10 μg/L aproptinin, 2 μg/L leupeptin and 100 μg/L pepstatin) and centrifuged at 700 × *g* for 10 min. The supernatant was then centrifuged at 10 000 × *g* for 20 min and the subsequent pellet containing mitochondria was resuspended in 70 μL homogenization buffer. The resultant supernatant was centrifuged at 100, 000 × *g* for 60 min with the supernatant taken as the cytosolic fraction and the pellet taken and resuspended as the microsomal fraction. Protein levels were quantified in subcellular fractions using standard Bradford assay. Samples containing 35 μg protein were loaded on 4--15% TGX^®^ gels (BioRad, CAN) and used for SDS-PAGE gel electrophoresis, then transferred onto 0.2 μm PVDF membranes for subsequent western blotting. Probing was done using primary antibodies against sEH (1:500, Elabscience; E-AB-60489), total-Akt (1:1000, Cell Signaling; CS9272S), phospho-Akt (Ser473) (1:1000, Cell Signaling; CS5106S), Sirt-3 (1:1000, Cell Signaling; CS5490S), total MnSOD (1:5000, Abcam; ab13533), acetyl-MnSOD (1:5000, Abcam; ab13707), α-tubulin (1:1000, Abcam, ab4074), mEH (1:200, Santa Cruz, sc135984), GAPDH (1:1000, Cell Signaling; CS2118S), and VDAC (1:1000, Abcam; ab14734). After washing with 1X TBST, membranes were incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies (1:5000) and visualized with ECL reagent. The densitometry analysis was performed based on relative band intensities using Image J software (NIH, United States).

Enzymatic Assays {#S2.SS4}
----------------

Sirt-3 activity was detected in the isolated mitochondrial fractions using a Sirt-3 fluorescent assay kit (BPS Bioscience, San Diego, CA, United States), according to the manufacturer's instructions. In this assay, mitochondria were first isolated from the hearts of young and aged male and female WT and sEH null mice. Mitochondria fractions were mixed with the specific HDAC fluorogenic substrate, bovine serum albumin, NAD^+^ and assay buffer. The deacetylation process induced by Sirt-3 in the sample sensitizes the HDAC substrate so that subsequent treatment with the Sirt-3 assay developer produces a fluorescence product that was measured using a fluorescence plate reader at 350/460 nm excitation/emission wavelengths. The activity of Sirt-3 was expressed as U/μg protein ([@B8]; [@B83]).

As an established biomarker of mitochondrial content, citrate synthase activity was measured spectrophotometrically as previously described ([@B3]). Briefly, heart tissues were ground and homogenized in ice-cold homogenization buffer (20 mM Tris, 40 mM KCl, 2 mM EGTA, pH7.4, with 50 mM sucrose added the day of homogenization) and centrifuged at 600 × *g* for 10 min. The supernatant was used to assess enzymatic activity spectrophotometrically as described previously ([@B72]).

SOD activity was measured in the cytosolic fractions using a spectrophotometry based assay dependent upon the competition for superoxide anion (O~2~^--^) by cytochrome c and SOD. The assay utilized xanthine and xanthine oxidase as the primary source of O~2~^--^. In this assay, one unit of SOD is equal to the amount of the enzyme which inhibits 50% of the rate of the reduction of cytochrome c ([@B26]; [@B7]).

Protein carbonyl content was assessed in cytosolic fractions based on a reaction with 2,4-dinitrophenylhydrazine derivatization (DNPH) using a protein carbonyl ELISA kit (Abcam; Ab1238536) following manufacturer specifications.

Mitochondrial Ultrastructure {#S2.SS5}
----------------------------

Conventional transmission electron microscopy (TEM) was used to assess mitochondrial ultrastructure. A 1--2mm^3^ sample of myocardial tissue was obtained mid-level from the left ventricular free wall and fixed at 4°C overnight in 3% glutaraldehyde and 3% paraformaldehyde. A mixture of 1.5% potassium ferrocyanide \[K~4~Fe (CN)\] and 2% osmium tetroxide (OsO~4~) in 0.1M cacodylate buffer was used as a post-fixative followed by staining en bloc with 2% uranyl acetate (pH 5.2) for 1 h. Tissues were dehydrated in a continuous series of ethyl alcohol (30, 50, 70, 80, 90, 95, and 100%) followed by acetone. Resin infiltration was obtained with serial dilutions of acetone:Spurr's resin (2:1; 1:1; 2:1; absolute Spurrs's resin). The samples were then thermally polymerized for 24 h at 70°C, followed by ultra-thin sectioning (70 nm thickness) using an ultramicrotome (Leica UC7, Leica Microsystems Inc., Vienna, Austria). Samples were post-stained with 4% uranyl acetate and Reinolds' lead citrate for 30 min followed by carbon-coating (Leica EM ACE600, Leica Microsystems Inc., Vienna, Austria). Sections were imaged at 60 kV using a transmission electron microscope (Hitachi H-7650 TEM, Hitachi High-Technologies Canada, Inc) equipped with a 16 megapixel EMCCD camera (XR111, Advanced Microscopy Technique, MA, United States) within 1 week of post-staining.

Statistical Analysis {#S2.SS6}
--------------------

Data were expressed as mean ± standard error of mean (SEM). Statistical significance (*P* \< 0.05) was determined by three-way ANOVA with Tukey's *post hoc* test. Statistical analysis was performed using GraphPad Prism 8 software (San Diego, CA, United States). Proportional variance (eta^2^, η^2^) obtained from three-way ANOVA is represented as a factor of 1, delineating contribution of age, sex or genotype to data set variability. Significance of variance and resultant interactions was set at *P* \< 0.05.

RESULTS {#S3}
=======

Age-Related Cardiac Hypertrophy Is Prevented in Aged sEH Null Female Mice {#S3.SS1}
-------------------------------------------------------------------------

Significant increases in body weight were observed in all aged mice of both sexes and genotypes ([Figure 1A](#F1){ref-type="fig"}). The ratio of heart weight (HW) to tibia length (TL) was used as an index of cardiac hypertrophy. There were no differences in cardiac weights between young WT and sEH null animals of either sex ([Figure 1B](#F1){ref-type="fig"}). Both aged male and female WT mice and male sEH null mice demonstrated significant increases in HW:TL; however, no increases were observed in aged female sEH null mice ([Figure 1B](#F1){ref-type="fig"}). While the Akt pathway has an important role as a pro-survival pathway, increased activation of Akt over aging has been shown to contribute to age-related cardiac hypertrophy and inflammation ([@B31]; [@B14]). Consistent with the literature, immunoblotting results indicated significantly increased levels of pAkt in the cytosolic fraction in aged mice ([Figure 1C](#F1){ref-type="fig"}).

![Physiological parameters in young and aged WT and sEH null mice. **(A)** Body weight (g) of mice, **(B)** Heart weight (HW) to tibia length (TL) HW:TL of mice, **(C)** Cytosolic phosphorylated Akt and total Akt protein expression in young and aged WT hearts and sEH null hearts. Values represent mean ± SEM, *n* = 5--8, *P* \< 0.05, ^∗^vs. young counterpart; ‡vs female counterpart.](fphys-11-00048-g001){#F1}

sEH Genetic Deletion Preserves Cardiac Function in Aged Mice {#S3.SS2}
------------------------------------------------------------

Characterization of aged and sex-related changes to cardiac function and parameters were obtained using 2D echocardiography. Results demonstrated there were no significant differences in heart rate between any of the groups. Yet, ejection fraction (% EF) and fractional shortening (% FS), markers of systolic function, significantly decreased in aged male and female WT mice as well as sEH null males ([Table 1](#T1){ref-type="table"}). Similarly, left ventricular end diastolic (LVEDV) and end systolic (LVESV) volumes and chamber internal diameters (LVID) increased in aged male and female WT mice and aged sEH null males, indicating a general decline in systolic function ([Table 1](#T1){ref-type="table"}). Interestingly, aged female sEH null mice were not different from young mice, indicating a general preservation of systolic function ([Table 1](#T1){ref-type="table"}). There were no significant changes in isovolumetric contraction or relaxation times (IVCT or IVRT) between any groups, but aortic ejection time (AET) was preserved only in aged male sEH null mice. The E/A ratio is a measure of mitral blood flow and is commonly used as a marker of diastolic function. E/A was significantly decreased in both WT male and female aged mice. Interestingly, the E/A ratio was significantly decreased in aged female but not male sEH null mice ([Table 1](#T1){ref-type="table"}). Similarly, E/E', a marker of LV filling pressure, was significantly decreased in female but not male mice. Together, these data suggest a divergent effect of sEH genetic deletion, with aged female mice exhibiting preserved systolic function and aged males exhibiting preserved diastolic function.

###### 

Cardiac functional parameters measured by 2D echocardiography.

                          WT              sEH null                                                                                              
  ----------------------- --------------- ----------------- --------------- ------------------ --------------- ---------------- --------------- -------------------
  HR, beats/min           460 ± 12        466 ± 7           459 ± 11        467 ± 9            461 ± 8         494 ± 9          479 ± 13        457 ± 15
  **Wall measurements**                                                                                                                         
  EF, %                   71.43 ± 1.90    61.62 ± 1.34\*    69.11 ± 2.03    57.95 ± 1.22\*     69.64 ± 1.66    65.15 ± 1.65     68.53 ± 1.49    57.41 ± 1.91\*‡
  FS, %                   40.53 ± 1.69    32.86 ± 0.93\*    38.63 ± 1.67    30.55 ± 0.83\*     38.85 ± 1.29    35.49 ± 1.21     37.94 ± 1.14    30.12 ± 1.27\*
  LVEDV, μl               55.34 ± 2.83    72.04 ± 3.79\*    72.34 ± 5.85‡   90.62 ± 2.35\*‡    59.28 ± 2.51    69.27 ± 3.41     62.92 ± 2.90    81.75 ± 4.39\*
  LVESV, μl               16.97 ± 1.61    28.29 ± 2.26\*    23.30 ± 2.86    37.63 ± 1.55\*‡    18.89 ± 1.64    24.28 ± 2.19     20.12 ± 1.46    35.69 ± 3.18\*‡
  CO, ml/min              17.78 ± 0.96    20.39 ± 1.01      22.13 ± 1.64    24.74 ± 0.87       18.66 ± 0.79    22.15 ± 0.86     19.90 ± 1.06    20.81 ± 0.68‡
  SV, μl                  38.37 ± 1.52    43.75 ± 1.82      49.03 ± 3.35‡   52.99 ± 1.58‡      40.41 ± 1.36    44.99 ± 1.59     42.80 ± 2.06    46.07 ± 1.85
  Corrected LV mass, mg   66.83 ± 3.60    107.65 ± 6.33\*   90.88 ± 7.71‡   142.51 ± 4.57\*‡   78.40 ± 3.01    99.73 ± 3.47\*   83.25 ± 3.05    117.38 ± 5.20\*\#
  LA, mm                  1.59 ± 0.08     2.06 ± 0.12\*     1.52 ± 0.09     2.17 ± 0.10\*      1.50 ± 0.07     1.98 ± 0.08\*    1.59 ± 0.08     2.14 ± 0.06\*
  IVS-diastole, mm        0.69 ± 0.03     0.86 ± 0.03\*     0.73 ± 0.03     0.85 ± 0.02        0.77 ± 0.02     0.85 ± 0.02      0.77 ± 0.03     0.74 ± 0.03
  IVS-systole, mm         1.13 ± 0.05     1.26 ± 0.05       1.19 ± 0.05     1.39 ± 0.03\*      1.16 ± 0.04     1.27 ± 0.04      1.15 ± 0.04     1.20 ± 0.03^\#^
  LVPW-diastole, mm       0.71 ± 0.03     0.88 ± 0.03\*     0.82 ± 0.04     0.96 ± 0.03\*      0.77 ± 0.03     0.86 ± 0.02      0.82 ± 0.03     0.90 ± 0.03
  LVPW-systole, mm        1.13 ± 0.04     1.27 ± 0.04       1.28 ± 0.06     1.34 ± 0.03        1.16 ± 0.04     1.25 ± 0.03      1.25 ± 0.04     1.20 ± 0.04
  LVID-diastole, mm       3.60 ± 0.08     4.02 ± 0.09\*     3.96 ± 0.14     4.45 ± 0.05\*‡     3.69 ± 0.07     3.94 ± 0.08      3.75 ± 0.10     4.25 ± 0.10\*
  LVID-systole, mm        2.16 ± 0.10     2.71 ± 0.09\*     2.44 ± 0.13     3.07 ± 0.05\*‡     2.27 ± 0.08     2.55 ± 0.09      2.34 ± 0.08     2.98 ± 0.12\*‡
  **Doppler Imaging**                                                                                                                           
  IVRT, ms                17.14 ± 0.97    16.83 ± 0.67      16.67 ± 1.64    15.62 ± 0.47       15.16 ± 0.60    15.06 ± 0.83     15.18 ± 0.78    15.61 ± 0.55
  IVCT, ms                12.99 ± 1.22    14.98 ± 0.92      15.00 ± 1.18    16.17 ± 1.03       13.61 ± 1.18    11.98 ± 0.84     12.30 ± 0.72    15.70 ± 0.69
  AET, ms                 51.70 ± 1.77    42.30 ± 1.03\*    48.91 ± 2.40    41.77 ± 0.95\*     50.07 ± 1.47    40.03 ± 0.81\*   46.02 ± 1.49    43.12 ± 1.31
  Tei index               0.581 ± 0.025   0.758 ± 0.029\*   0.663 ± 0.049   0.766 ± 0.024      0.574 ± 0.022   0.678 ± 0.034    0.604 ± 0.024   0.727 ± 0.020
  E/A                     1.88 ± 0.06     1.55 ± 0.06\*     1.75 ± 0.09     1.44 ± 0.05\*      1.68 ± 0.06     1.43 ± 0.05\*    1.63 ± 0.03     1.50 ± 0.03
  E′/A′                   1.32 ± 0.07     1.22 ± 0.05       1.27 ± 0.09     1.17 ± 0.07        1.39 ± 0.12     1.25 ± 0.11      1.21 ± 0.05     1.09 ± 0.07
  E′                      22.40 ± 1.44    23.21 ± 1.05      24.95 ± 1.58    22.16 ± 1.17       22.01 ± 1.29    25.55 ± 1.51     23.49 ± 1.75    20.72 ± 1.47
  E/E′                    30.48 ± 2.06    22.70 ± 1.14\*    29.98 ± 2.22    25.43 ± 1.50       29.87 ± 1.43    26.41 ± 1.04     31.03 ± 2.22    32.29 ± 2.35
  *n* number              20              24                13              31                 20              21               20              17

Data is shown as mean ± SEM,

P

\< 0.05, \* vs. young counterpart; \#vs, WT counterpart; ‡vs, female counterpart.

Aging Affects the Protein Expression of Epoxide Hydrolases {#S3.SS3}
----------------------------------------------------------

No expression of sEH was detected in either young or aged hearts from null mice confirming genetic deletion ([Figure 2A](#F2){ref-type="fig"}). sEH expression was significantly increased in aged male WT mice but not in aged females ([Figure 2A](#F2){ref-type="fig"}). Interestingly, our data demonstrated a significant increase in mEH expression in both aged WT and sEH null females, as well as aged WT males ([Figure 2B](#F2){ref-type="fig"}). However, this increase was not observed in aged sEH null males, who had significantly decreased mEH expression compared to aged WT males ([Figure 2B](#F2){ref-type="fig"}). Epoxide hydrolases have an important role in renal epoxylipid metabolism; as renal function is important to overall cardiovascular health, we assessed changes in sEH and mEH in kidneys ([@B33]). There was no expression of sEH observed in kidneys from sEH null mice ([Figure 2C](#F2){ref-type="fig"}). Correlating with previous literature, renal sEH expression was significantly increased in WT males compared to females but there were no differences between young and aged mice ([Figure 2C](#F2){ref-type="fig"}; [@B69]). Renal mEH was not significantly altered in any group ([Figure 2D](#F2){ref-type="fig"}).

![Protein expression of epoxide hydrolases in WT and sEH null mice. Representative immunoblots and quantitation for cardiac soluble epoxide hydrolase (sEH, **A**) and microsomal epoxide hydrolase (mEH, **B**). Representative immunoblots for renal sEH **(C)** and mEH **(D)**. Protein expression of sEH was normalized to GAPDH. Protein expression of mEH was normalized to α-tubulin. Data represented as mean ± SEM, *n* = 4--5, *P* \< 0.05, ^∗^\*vs. young counterpart; ‡vs. female group.](fphys-11-00048-g002){#F2}

Sirt-3 Activity and Acetylated MnSOD Are Preserved in Aged sEH Null Female Mice {#S3.SS4}
-------------------------------------------------------------------------------

Sirt-3, the main mitochondrial deacetylase, has been found to be down-regulated with aging and associated with increased ROS levels correlating with a decline in cardiac function ([@B11]; [@B80]). In the current study, there were no differences observed in mitochondrial Sirt-3 protein expression in any group ([Figure 3A](#F3){ref-type="fig"}). However, Sirt-3 activity was significantly decreased in hearts from aged WT females, with a similar trend in males (*P* = 0.0726). Interestingly, Sirt-3 activity was preserved in aged sEH null mice compared to their young counterparts and aged sEH null females had significantly higher Sirt-3 activity than similarly aged WT females ([Figure 3B](#F3){ref-type="fig"}). The age-dependent changes in Sirt-3 result in reduction in the level of activated MnSOD resulting in increased oxidative stress ([@B31]). Consistent with previous studies, the expression level of AcMnSOD significantly increased in an age-dependent manner in both male and female WT hearts ([Figure 3C](#F3){ref-type="fig"}). Interestingly, AcMnSOD expression was lower in sEH null mice compared to their WT counterparts ([Figure 3C](#F3){ref-type="fig"}). Both aged male and female sEH null mice demonstrated increased AcMnSOD levels but these were significantly lower than the corresponding aged WT mice ([Figure 3C](#F3){ref-type="fig"}). In accordance with literature, cardiac SOD activity was significantly decreased in both male and female WT aged animals ([Figure 3D](#F3){ref-type="fig"}). SOD activity was preserved in aged sEH null animals compared to the young null mice ([Figure 3D](#F3){ref-type="fig"}). These data suggest sEH genetic deletion confers protection against oxidative stress by preserving Sirt3 activity, which will decrease AcMnSOD levels resulting in maintained SOD activity. This was partially supported by assessment of protein carbonylation as a biomarker of oxidative stress ([@B25]), where increased levels of protein carbonyl were only observed in aged male animals regardless of their genotype and not in aged female hearts ([Figure 3E](#F3){ref-type="fig"}). Renal AcMnSOD and Sirt-3 expression remained unchanged in all groups with age ([Figures 4A,B](#F4){ref-type="fig"}).

![Sirtuin-3 and SOD in young and aged WT and sEH null mice. **(A)** Cardiac Sirt-3 protein expression in young and aged WT and sEH null mice. **(B)** Sirt-3 activity in young and aged WT and sEH null mice was determined in mitochondrial fractions. **(C)** Relative protein expression of AcMnSOD normalized to total MnSOD in young and aged WT hearts and sEH null hearts. **(D)** Superoxide dismutase (SOD) activity was assessed in cytosolic fractions from young and aged WT and sEH null hearts. **(E)** Protein carbonylation levels were assessed in cardiac cytosolic fractions from young and aged WT and sEH null hearts. Data represented as mean ± SEM, *n* = 4--8, *P* \< 0.05, ^∗^vs young counterpart; \#vs WT counterpart; ‡vs female counterpart.](fphys-11-00048-g003){#F3}

![Renal expression of mitochondrial Sirt-3 compared to VDAC **(A)** and Acetylated MnSOD **(B)** compared to total MnSOD. Data represented as mean ± SEM, *n* = 3, *P* \< 0.05.](fphys-11-00048-g004){#F4}

Cardiac Mitochondrial Ultrastructure Is Preserved in Aged Female sEH Null Mice {#S3.SS5}
------------------------------------------------------------------------------

To obtain an estimate of cardiac mitochondrial content, we measured the activity of citrate synthase, a rate-limiting enzyme involved in mitochondrial oxidative metabolism ([@B43]). There were no differences in citrate synthase activity in any group suggesting the overall mitochondrial content was not significantly altered ([Figure 5A](#F5){ref-type="fig"}). Conventional TEM was employed to assess mitochondrial ultrastructure in the left ventricular free wall of both young and aged mice. Marked alterations in mitochondrial ultrastructure, exemplified by decreased cristae density, disturbed arrangement in the myofibrillar spaces and enlarged size, were observed in both male and female aged WT hearts ([Figures 5B--E](#F5){ref-type="fig"}). The age-related changes to mitochondrial morphology were absent in sEH null animals ([Figures 5F--I](#F5){ref-type="fig"}).

![Mitochondrial content and ultrastructure in hearts from young and aged WT and sEH null mice. **(A)** Citrate synthase activity level as a biomarker of mitochondrial content in young and aged WT and sEH null mice was determined spectrophotometrically, data are represented as mean ± SEM, *n* = 5--8. Representative transmission electron micrograph images from WT **(B--E)** and sEH null **(F--I)** mice at two magnifications, 3000X (left) and 7000X (right), *n* = 1 per group.](fphys-11-00048-g005){#F5}

Age Is a Crucial Variable in Cardiac Function and Oxidative Stress Responses {#S3.SS6}
----------------------------------------------------------------------------

Variance (η^2^) from three-way ANOVA (age x genotype x sex) and resultant significance are listed in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, respectively. Of the three variables assessed in this study, age exhibited the greatest significant effect over the majority of parameters assessed ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). Sex was also a significant contributor to the effects observed in cardiac systolic function, Sirt-3 activity and epoxide hydrolase expression ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). Genotype demonstrated significant effects on heart weight, cardiac Sirt-3 activity, and SOD activity and diastolic cardiac function ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). Interaction effects delineate the effect of one variable, such as age, on the impact of another, such as genotype, for any parameter in question. When an interaction is significant for a given parameter, it suggests the impact depends on the presence of the other factor. Important interaction effects between age, genotype and sex are described in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}. There was no interaction between all three variables for any factor (data not shown). These data support the evidence demonstrating the importance of age and sex in cardiac function.

###### 

Proportional variance (η^2^) values for age, genotype and sex as assessed by three-way ANOVA.

  Variable                                   Age          Genotype     Sex          Age × Genotype   Age × Sex    Genotype × Sex
  ------------------------------------------ ------------ ------------ ------------ ---------------- ------------ ----------------
  **Physiological parameters**                                                                                    
  Body weight (g)                            **0.4993**   0.0011       **0.0732**   0.0005           0.0010       0.0041
  HW:TL, mg/mm                               **0.2825**   **0.0233**   **0.1745**   **0.0332**       **0.0258**   ns
  HR, beats/min                              0.0040       0.0105       0.0020       ns               0.0191       0.0021
  **Protein expression**                                                                                          
  pAKT/AKT                                   **0.5828**   0.0029       0.0355       0.0253           0.0046       0.0022
  Cardiac sEH                                **0.0185**   **0.8821**   **0.0092**   **0.0185**       0.0080       **0.0092**
  Cardiac mEH                                **0.5598**   0.0437       **0.0617**   0.0352           0.0326       0.0157
  Renal sEH                                  0.0003       **0.6771**   **0.1524**   0.0003           0.0001       **0.1524**
  Renal mEH                                  **0.3350**   0.0178       0.0036       0.0022           0.0043       0.0312
  Cardiac Sirt-3                             0.0012       0.0060       0.0096       0.0457           0.0160       0.0108
  Cardiac AcMnSOD                            **0.4116**   **0.3121**   0.0004       0.0023           0.0007       0.0029
  Renal Sirt-3                               0.0133       0.0565       0.0293       0.0023           0.0491       0.0304
  Renal AcMnSOD                              0.1294       0.0681       0.0015       0.0049           0.0478       0.0231
  **Enzymatic activity**                                                                                          
  Cardiac Sirt-3, U ⋅ μg^--1^                **0.2208**   **0.0643**   **0.0598**   **0.0562**       ns           0.0209
  SOD, U ⋅ mg^--1^                           **0.3586**   **0.1958**   **0.1017**   **0.0708**       0.0123       0.0033
  Protein Carbonylation, nmol ⋅ mg^--1^      **0.0800**   ns           0.0337       0.0365           **0.2499**   **0.1725**
  Citrate Synthase, nmol ⋅ min^--1^mg^--1^   **0.1827**   **0.1680**   0.0481       0.0001           0.0063       0.0009
  **2D ECHO: Wall measurements**                                                                                  
  EF,%                                       **0.2549**   0.0001       **0.0420**   0.0055           0.0121       0.0016
  FS,%                                       **0.2476**   ns           **0.0374**   0.0071           0.0081       0.0015
  LVEDV, μl                                  **0.1663**   0.0119       **0.1092**   0.0016           0.0045       **0.0155**
  LVESV, μl                                  **0.2293**   0.0055       **0.0846**   0.0023           **0.0183**   0.0010
  CO, ml/min                                 **0.0575**   0.0078       **0.0460**   0.0004           0.0042       **0.0481**
  SV, μl                                     **0.0492**   0.0163       **0.0910**   0.0004           0.0012       **0.0449**
  Corrected LV mass, mg                      **0.3063**   **0.0119**   **0.0928**   **0.0192**       0.0078       **0.0186**
  LA, mm                                     **0.3451**   0.0011       0.0064       0.0005           0.0041       0.0032
  IVS-diastole, mm                           **0.1061**   0.0000       0.0057       **0.0521**       **0.0278**   **0.0245**
  IVS-systole, mm                            **0.0800**   0.0122       0.0043       0.0099           0.0000       **0.0281**
  LVPW-diastole, mm                          **0.1490**   0.0004       **0.0493**   0.0130           0.0006       0.0071
  LVPW-systole, mm                           **0.0249**   0.0109       **0.0283**   0.0101           0.0184       0.0140
  LVID-diastole, mm                          **0.1769**   0.0099       **0.0866**   0.0012           0.0059       0.0108
  LVID-systole, mm                           **0.2497**   0.0034       **0.0737**   0.0033           0.0112       0.0013
  **2D ECHO: Doppler imaging**                                                                                    
  IVRT, ms                                   0.0011       **0.0299**   0.0013       0.0030           ns           0.0055
  IVCT, ms                                   0.0140       0.0176       0.0181       0.0011           0.0101       0.0004
  AET, ms                                    **0.2371**   0.0081       0.0050       0.0035           **0.0241**   0.0015
  Tei index                                  **0.1613**   **0.0214**   0.0179       0.0017           0.0020       0.0001
  E/A                                        **0.1864**   **0.0246**   0.0082       0.0103           0.0042       0.0117
  E′/A′                                      0.0237       0.0002       0.0207       0.0003           0.0000       0.0066
  E′                                         0.0006       0.0004       0.0014       0.0030           **0.0394**   0.0095
  E/E′                                       **0.0494**   **0.0284**   0.0201       **0.0241**       0.0148       0.0054

Variances are reported as a fraction of 1. Bolded values represent variances that reach a statistically significant contribution of the total variability,

P

\< 0.05.

###### 

*P*-values from three-way ANOVA statistical analysis of data-set variability.

  Variable                                   Age            Genotype       Sex            Age × Genotype   Age × Sex    Genotype × Sex
  ------------------------------------------ -------------- -------------- -------------- ---------------- ------------ ----------------
  **Physiological parameters**                                                                                          
  Body weight (g)                            **\<0.0001**   0.4404         **\<0.0001**   0.5936           0.4583       0.1366
  HW:TL, mg/mm                               **\<0.0001**   **0.0474**     **\<0.0001**   **0.0190**       **0.0374**   0.9715
  HR, beats/min                              0.4141         0.1860         0.5623         0.9422           0.0755       0.5523
  **Protein expression**                                                                                                
  pAKT/AKT                                   **\<0.0001**   0.5743         0.0556         0.1034           0.4802       0.6218
  Cardiac sEH                                **0.0043**     **\<0.0001**   **0.0371**     **0.0043**       0.0513       **0.0371**
  Cardiac mEH                                **\<0.0001**   0.0771         **0.0384**     0.1103           0.1235       0.2783
  Renal sEH                                  0.6159         **\<0.0001**   **\<0.0001**   0.6159           0.7943       **\<0.0001**
  Renal mEH                                  **0.0075**     0.4902         0.7553         0.8066           0.7332       0.3642
  Cardiac Sirt-3                             0.8365         0.6480         0.5653         0.2143           0.4585       0.5423
  Cardiac AcMnSOD                            **\<0.0001**   **\<0.0001**   0.8027         0.5654           0.7577       0.5196
  Renal Sirt-3                               0.6153         0.3061         0.4578         0.8346           0.3391       0.4496
  Renal AcMnSOD                              0.1080         0.2347         0.8553         0.7437           0.3160       0.4819
  **Enzymatic activity**                                                                                                
  Cardiac Sirt-3, U ⋅μg^--1^                 **\<0.0001**   **0.0187**     **0.0231**     **0.0275**       0.9616       0.1730
  SOD, U ⋅ mg^--1^                           **\<0.0001**   **0.0013**     **0.0140**     **0.0360**       0.3605       0.6308
  Protein carbonylation, nmol ⋅ mg^--1^      **0.0496**     0.9944         0.1923         0.1753           **0.0012**   **0.0056**
  Citrate synthase, nmol ⋅ min^--1^mg^--1^   **0.0133**     **0.0170**     0.1819         0.9639           0.6240       0.8539
  **2D ECHO: Wall measurements**                                                                                        
  EF,%                                       **\<0.0001**   0.8915         **0.0017**     0.2520           0.0885       0.5388
  FS,%                                       **\<0.0001**   0.9607         **0.0034**     0.1970           0.1686       0.5572
  LVEDV, μl                                  **\<0.0001**   0.0836         **\<0.0001**   0.5300           0.2893       **0.0491**
  LVESV, μl                                  **\<0.0001**   0.2324         **\<0.0001**   0.4358           **0.0295**   0.6135
  CO, ml/min                                 **0.0010**     0.2195         **0.0031**     0.7773           0.3677       **0.0025**
  SV, μl                                     **0.0017**     0.0674         **\<0.0001**   0.7803           0.6119       **0.0026**
  Corrected LV mass, mg                      **\<0.0001**   **0.0379**     **\<0.0001**   **0.0087**       0.0919       **0.0098**
  LA, mm                                     **\<0.0001**   0.6172         0.2364         0.7435           0.3450       0.4060
  IVS-diastole, mm                           **\<0.0001**   0.9723         0.3089         **0.0024**       **0.0252**   **0.0357**
  IVS-systole, mm                            **0.0001**     0.1253         0.3639         0.1670           0.9575       **0.0208**
  LVPW-diastole, mm                          **\<0.0001**   0.7640         **0.0014**     0.0969           0.7176       0.2189
  LVPW-systole, mm                           **0.0351**     0.1611         **0.0250**     0.1785           0.0694       0.1128
  LVID-diastole, mm                          **\<0.0001**   0.1205         **\<0.0001**   0.5948           0.2308       0.1058
  LVID-systole, mm                           **\<0.0001**   0.3423         **\<0.0001**   0.3524           0.0875       0.5627
  **2D ECHO: Doppler imaging**                                                                                          
  IVRT, ms                                   0.6663         **0.0276**     0.6412         0.4789           0.9306       0.3423
  IVCT, ms                                   0.1210         0.0825         0.0785         0.6611           0.1865       0.8040
  AET, ms                                    **\<0.0001**   0.1804         0.2914         0.3758           **0.0217**   0.5603
  Tei index                                  **\<0.0001**   **0.0379**     0.0573         0.5511           0.5252       0.9008
  E/A                                        **\<0.0001**   **0.0233**     0.1893         0.1401           0.3476       0.1164
  E′/A′                                      0.0540         0.8518         0.0713         0.8288           0.9445       0.3068
  E′                                         0.7670         0.8147         0.6478         0.4998           **0.0155**   0.2318
  E/E′                                       **0.0045**     **0.0301**     0.0670         **0.0455**       0.1154       0.3413

Bolded values represent variables that elicit statistically significant effects on the parameter in question,

P

\< 0.05.

DISCUSSION {#S4}
==========

Biological aging is a natural process resulting in marked changes to an individual's ability to overcome stress, which worsen adverse outcomes such as increased CVD risk ([@B54]). Although the underlying mechanisms behind cardiac aging remain elusive, mitochondrial dysfunction is hypothesized to be a major contributor ([@B13]). In particular, age-associated mitochondrial damage leading to increased ROS production damaging mitochondrial DNA and proteins as well affecting quality control processes, ultimately contributing to decreased cardiac function ([@B61]; [@B18]; [@B73]). Importantly, sex and gender differences are known to affect the etiology, presentation and prognosis of CVDs as individuals age ([@B66]; [@B56]; [@B77]). Unique CVD risks for women include the cessation of menarche (menopause), preeclampsia, gestational diabetes and certain autoimmune inflammatory disorders, such as systemic lupus erythematosus ([@B1]). While men on average present with CVD at a younger age, evidence suggests CVD risk factors such as hypertension and diabetes play a greater role in disease acceleration in women ([@B17]). A further understanding and characterizing potential sex-specific mechanisms contributing to cardiac aging may provide new insights for the optimal prevention and management of age-related CVDs. Consistent with literature, we report sex-differences in the age-associated development of myocardial hypertrophy and deterioration of cardiac function; however, we demonstrate novel data highlighting the beneficial effect of deleting sEH.

In humans, sex-dependent differences in cardiac aging indicate males on average exhibit greater impaired systolic function coupled with increased wall thickness, cavity dimension and LV mass ([@B50]). Conversely women display a greater degree of diastolic impairment coupled with increased concentric remodeling, with systolic impairment occurring later than in their male counterparts ([@B42]; [@B17]). Murine models are unable to replicate changes in blood pressure and blood cholesterol often present in human patients with CVD; however, they are a useful model recapitulating many human age-related changes in cardiac structure and function, such as increased LV mass, decreased diastolic filling ratios and reduced fractional shortening ([@B20]). In the present study, we observed a significant decline in systolic and diastolic parameters coupled with a significant increase in LV mass in aged male and female WT mice. These data are consistent with what is observed clinically in aging humans. Interestingly, aged female sEH null mice demonstrated preserved systolic function and LV mass but exhibited diastolic dysfunction. Conversely, aged male sEH null mice demonstrated a significant reduction in systolic function but no significant change in diastolic parameters. Previously, we demonstrated cardioprotective effects in aged sEH null mice following myocardial infarction ([@B36]). This previous study used combined males and females and was not designed to assess sex differences, but rather generalized aging effects in an injury model. The present data suggest important sex-specific differences in cardiac aging following sEH genetic deletion in the absence of any defined disease state.

Sexual dimorphism in sEH expression and activity has been documented in the renal, hepatic and cardiovascular systems in young rodent models ([@B60]; [@B69]; [@B81]; [@B63]; [@B79]), yet the exact mechanism(s) behind these differences remain unknown. Recent studies have demonstrated estrogen/estrogen receptor mediated methylation of the sEH promoter region causes gene silencing in female rodents ([@B79]). This epigenetic silencing of sEH expression may be responsible for some sexual dimorphism observed in young animal models, although whether this occurs in aged animals is unknown. In the current study, we observed an increase in sEH expression in aged WT males that was absent in WT females. In addition, there was an age-related increase in mEH expression in WT mice and sEH null females, but not sEH null males. The increased mEH expression in females may be a compensatory response to the sEH deletion but it is unknown why this does not occur in aged sEH null males. The role of mEH in cardiac eicosanoid metabolism has only recently been investigated *in vivo*. Early data suggested sEH demonstrated a higher catalytic ability compared to mEH and played the predominate role in epoxylipid metabolism ([@B71]; [@B46]; [@B28]). In contrast, mEH had been considered an important mediator of xenobiotic metabolism, with limited contribution to cardiac epoxylipid metabolism ([@B46]). Recent data from Edin et al. suggested under basal conditions it is substrate availability rather than catalytic activity that drives epoxylipid metabolism ([@B23]). Cell injury caused by stressors such as ischemia can promote the release of free arachidonic acid, where sEH plays the dominate role in epoxylipid metabolism. Conversely, under basal or physiological conditions mEH may act as a "first-pass" hydrolase to remove the small amount of endogenous epoxylipids produced ([@B23]). Furthermore, they suggest while tethering of mEH to the microsomes may hinder its ability to scavenge epoxylipids from the cytosol, epoxylipids bound in the microsomes will be in close proximity. Interestingly, the current study demonstrates both mEH and sEH significantly increased in aged WT males but only mEH increased in aged WT and sEH null females. Whether these differences with age and sex are related to changes in epoxylipid formation, shifts in epoxylipid storage or alterations in enzymatic catalytic activity remain unknown and are the subject of ongoing research. Interestingly, female sEH null mice were protected against aged-dependent development of hypertrophy and had preserved cardiac systolic function, while aged sEH null male mice were not protected against hypertrophy but demonstrated preserved diastolic function.

Mitochondria are powerful organelles essential for maintaining cardiac function through oxidative phosphorylation and ATP generation; however, they are also the main site of ROS production ([@B16]; [@B68]). During the aging process in both mice and humans cardiac ROS production outpaces mitochondrial scavenging capacity correlating with the decline in function ([@B55]; [@B10]). Evidence of sex specific differences in mitochondrial function and morphology have been observed in healthy and diseased states but the underlying molecular mechanisms remain poorly understood ([@B37]). For example, cardiomyocytes from female rats have been found to possess lower mitochondrial content yet exhibit more efficient mitochondria compared to males ([@B19]). Furthermore, female rats show lower levels of mitochondrial hydrogen peroxide in liver and brain ([@B9]). In the current study, an age-related increase in the level of protein carbonylation was observed in males indicating a significant increase in cardiac oxidative stress. MnSOD is the primary mitochondrial antioxidant enzyme that contributes to maintaining mitochondrial function; moreover, inactivation of the MnSOD gene in mice results in neonatal lethality ([@B45]; [@B12]). In rat brain and liver, higher expression and activity of MnSOD in females is associated with lower oxidative damage ([@B9]). The activation of MnSOD is primarily regulated through its deacetylation via Sirt-3, which is the predominant mitochondrial deacetylase ([@B57]). Sirt-3 deficient mice demonstrate mitochondrial dysfunction and excessive production of ROS as well cardiac fibrosis and hypertrophy ([@B74]; [@B76]). It has been reported that the hyperacetylation and deactivation of mitochondrial proteins including MnSOD over aging is associated with a decline in Sirt-3 activity ([@B57]). The decline in Sirt-3 activity coupled with a significant increase in expression of AcMnSOD in aged WT animals is consistent with the literature. Importantly, our data demonstrated sEH deletion preserved Sirt-3 activity in aged mice and was associated with reduced expression of AcMnSOD. Moreover, SOD activity was reduced significantly in WT mice but not in sEH null mice. Importantly, the increased antioxidant activity of mitochondrial SOD observed in sEH null mice correlated with better mitochondrial ultrastructure. Recent evidence suggests Sirt-3 potentially has a role in limiting cardiac hypertrophy as it is found to be downregulated in mouse hypertrophic hearts ([@B15]; [@B40]). Sirt-3 mediated activation of MnSOD and subsequent ROS scavenging is proposed to suppress hypertrophic signaling, such as the PI3K/Akt pathway ([@B59]). Interestingly, the increase in cardiac pAkt expression observed in all aged mice did not correlate with the oxidative stress or hypertrophic responses observed in the aged mice. Thus, these data suggest the genetic deletion of sEH provided a better capacity for cardiac mitochondria to limit potential aged-related damage, which was independent of an Akt pathway.

Many of the protective effects attributed to sEH gene deletion have been associated with increased epoxylipid levels, such as increased levels of epoxysatrienoic acids (EETs). Peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC-1α) is known to mediate mitochondrial function, oxidative stress and Sirt-3 expression ([@B41]). In models of obesity, EETs have been shown to activate PGC-1α, resulting in preserved mitochondrial structural and functional proteins associated with preserved Sirt-3 expression ([@B70]). In the present study, while we observed no change in Sirt-3 expression, we observed a preservation of Sirt-3 activity. These data suggest there may be post-translational modification(s) of Sirt-3 associated with sEH genetic deletion and subsequent altered epoxylipid metabolism that are independent to the effects mediated through PGC-1α. Pillai et al. reported the biophenolic compound hokoniol is capable of passing through mitochondrial membranes to directly bind Sirt-3, improving affinity of Sirt-3 binding and utilization of NAD^+^, ultimately preserving its deacetylase activity ([@B70]; [@B4]). Preservation of Sirt-3 activity observed in sEH null mice has not previously been reported. While the mechanisms responsible for the age-dependent preservation of Sirt-3 activity observed in sEH null mice is unknown, we propose a resulting increase in epoxylipid metabolites have a role in conserving the deacetylase activity of Sirt-3 over aging.

In the current study, we characterize the effect and sexual dimorphisms of sEH deletion in cardiac aging. The data demonstrated aged sEH null mice have preserved Sirt-3 activity, decreased AcMnSOD levels and better mitochondrial ultrastructure compared to WT mice. Interestingly, sEH null females had preserved systolic function and no cardiac hypertrophy, while sEH null male mice had preserved diastolic function. Increased expression of sEH was observed in WT males and marked increases in mEH expression where found in both genotypes. While further studies are necessary to elucidate the mechanism(s) behind these effects, the data highlight novel sexual dimorphic patterns of cardiac aging.
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